-
The Indian state of Gujarat approves a 5GW solar park project
Time of Update: 2022-12-27
(This article first published cable network: /, please indicate the source for reprinting)/ The minister also noted that the project is located on 11,000 hectares of land along DSIR's Khambhat Bay and will attract investment amounting to INR 250 billion while creating jobs for more than 20,000 people.
-
The largest photovoltaic power generation project in Longyan City settled in Changting
Time of Update: 2022-11-22
Changting County vigorously develops clean energy photovoltaic power generation projects, and the introduction of Shenhua Group will rely on the rooftop photovoltaic power station project of Changting Industrial Park (Tengfei Industrial Park) of the high-tech zone of the first phase of the project, and build photovoltaic power stations on the idle roofs of enterprises in the park, in the form of an annual rent of 1.
-
Jinneng Technology will build 2×350,000 tons/year and 2×450,000 tons/year PP projects in the same period
Time of Update: 2022-08-29
; the second phase of 900,000 tons/year propane dehydrogenation unit is under construction ; the south plant area is adjacent to Gangchang West Road in the west, Jiji Road and the planned industrial land in the park in the south, The side is Gangchang Road, covering an area of about 111.
-
The Coastal Industrial Park of Binhai County, Jiangsu Province continues to promote the improvement of the chemical industry
Time of Update: 2021-06-17
Global Coatings Network News: Since the beginning of this year, the Coastal Industrial Park of Binhai County, Jiangsu Province has been guided by the provincial and municipal chemical park renovation work plan, with a firm attitude, decisive action, and effective measures to continue to promote the renovation of the chemical industry and continue to move towards a new stage of high-quality development.
-
Palbociclib, Pfizer's CDK4 / 6 inhibitor, has the priority of FDA approval
Time of Update: 2014-10-14
Source: US and Chinese drug sources on October 14, 2014, Pfizer today announced that its CDK4 / 6 inhibitor, palbociclib, as a first-line drug for ER positive and HER2 negative breast cancer, has obta
